Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
RegulatoryapprovedLibre Duo 10 DayPositive
AI Analysis
Summary
Abbott received FDA authorization for Libre Duo 10 Day, a first-of-its-kind biowearable that simultaneously monitors glucose and ketone levels to help prevent diabetic ketoacidosis in people with diabetes.
Outcome Details
FDA authorization for dual glucose-ketone sensing biowearable technology
Importance:8/10
Sentiment:
0.90
FDA approvaldiabetesmedical devicewearable technologyketone monitoringDKA prevention
Related Companies
Read the original article
Published by PR Newswire Pharma on August 25, 2026 6:49 PM